RxDoctor Payments Data

Ariele Greenfield, MD

Neurology · Mountain View, CANPI 1114214566

Payments from drug & device makers

$207,677in general payments, 2019–2025

Across 43 payments — averaging $4829.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$203K
  • Genentech USA, Inc.$2K
  • TG Therapeutics, Inc.$1K
  • F. Hoffmann-la Roche AG$1K
  • AstraZeneca$285
  • Biogen$225
  • plus $78 from 3 others

What the payments were for

  • Consulting fees$9,12394%
  • Food & beverage$5606%
  • Education$571%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$207,677 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$66,932
Medicare patients
144
Services billed
2,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate21$185,669
AubagioTeriflunomide12$114,522
Nurtec OdtRimegepant Sulfate11$35,071
Teriflunomide15$24,783
Emgality PenGalcanezumab-Gnlm11$12,875
Dalfampridine ErDalfampridine34$7,888
Memantine Hcl57$4,018
Carbidopa-LevodopaCarbidopa/Levodopa111$3,104
Baclofen26$1,452
Carbamazepine31$1,307
Levetiracetam34$1,287
Gabapentin63$1,239
Donepezil Hcl69$890
PrometheganPromethazine Hcl12$673
Sumatriptan Succinate15$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$225$185,66921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →